Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks ...

The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

Key points Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.